Rare osteoarthritis: Ochronosis and Kashin-Beck disease

Rheumatology: Sixth Edition

Volumn 2-2, Issue , 2015, Pages 1536-1547

  Kraus, Virginia Byers ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84927695738     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-09138-1.00185-6     Document Type: Chapter

References (154)

1. Mannoni A, Selvi E, Lorenzini S, et al. Alkaptonuria, ochronosis, and ochronotic arthropathy. Semin Arthritis Rheum 2004, 33:239-248.
2. Phornphutkul C, Introne WJ, Perry MB, et al. Natural history of alkaptonuria. N Engl J Med 2002, 347:2111-2121.
3. Rosenberg LE Legacies of Garrod's brilliance. One hundred years-and counting. J Inherit Metab Dis 2008, 31:574-579.
4. Kobak AC, Oder G, Kobak S, Argin M, Inal V Ochronotic arthropathy: disappearance of alkaptonuria after liver transplantation for hepatitis B-related cirrhosis. J Clin Rheumatol 2005, 11:323-325.
5. Watts RW, Watts RA Alkaptonuria: a 60-yr follow-up. Rheumatology (Oxford) 2007, 46:358-359.
6. Stenn FF, Milgram JW, Lee SL, Weigand RJ, Veis A Biochemical identification of homogentisic acid pigment in an ochronotic Egyptian mummy. Science 1977, 197:566-568.
7. Lamy S Orphan Drugs: final study. European Parliament. Directorate General for Research 1999.
8. Keller JM, Macaulay W, Nercessian OA, Jaffe IA New developments in ochronosis: review of the literature. Rheumatol Int 2005, 25:81-85.
9. Uyguner O, Goicoechea de Jorge E, Cefle A, et al. Molecular analyses of the HGO gene mutations in Turkish alkaptonuria patients suggest that the R58fs mutation originated from central Asia and was spread throughout Europe and Anatolia by human migrations. J Inherit Metab Dis 2003, 26:17-23.
10. Al-Sbou M, Mwafi N, Lubad MA Identification of forty cases with alkaptonuria in one village in Jordan. Rheumatol Int 2011, 32:3737-3740.
11. Hunter T, Gordon DA, Ogryzlo MA The ground pepper sign of synovial fluid: a new diagnostic feature of ochronosis. J Rheumatol 1974, 1:45-53.
12. Peker E, Yonden Z, Sogut S From darkening urine to early diagnosis of alkaptonuria. Indian J Dermatol Venereol Leprol 2008, 74:700.
13. Burkhart C, Burkhart C Ochronosis. eMedicine Specialities [serial on the Internet] 2005.
14. Vijaikumar M, Thappa DM, Srikanth S, Sethuraman G, Nadarajan S Alkaptonuric ochronosis presenting as palmoplantar pigmentation. Clin Exp Dermatol 2000, 25:305-307.
15. Hamdi N, Cooke TD, Hassan B Ochronotic arthropathy: case report and review of the literature. Int Orthop 1999, 23:122-125.
16. Perry MB, Suwannarat P, Furst GP, Gahl WA, Gerber LH Musculoskeletal findings and disability in alkaptonuria. J Rheumatol 2006, 33:2280-2285.
17. Orzincolo C, Castaldi G, Scutellari PN, et al. [Ochronotic arthropathy in alkaptonuria. Radiological manifestations and physiopathological signs]. Radiol Med 1988, 75:476-481.
18. Konttinen YT, Hoikka V, Landtman M, et al. Ochronosis: a report of a case and a review of literature. Clin Exp Rheumatol 1989, 7:435-444.
19. Forslind K, Wollheim FA, Akesson B, Rydholm U Alkaptonuria and ochronosis in three siblings. Ascorbic acid treatment monitored by urinary HGA excretion. Clin Exp Rheumatol 1988, 6:289-292.
20. Filippou G, Frediani B, Selvi E, Bertoldi I, Galeazzi M Tendon involvement in patients with ochronosis: an ultrasonographic study. Ann Rheum Dis 2008, 67:1785-1786.
21. Chua SY, Chang HC Bilateral spontaneous rupture of the quadriceps tendon as an initial presentation of alkaptonuria-a case report. Knee 2006, 13:408-410.
22. Aliberti G, Pulignano I, Schiappoli A, et al. Bone metabolism in ochronotic patients. J Intern Med 2003, 254:296-300.
23. Helliwell TR, Gallagher JA, Ranganath L Alkaptonuria-a review of surgical and autopsy pathology. Histopathology 2008, 53:503-512.
24. Zhao BH, Chen BC, Shao DC, Zhang Q Osteoarthritis? Ochronotic arthritis! A case study and review of the literature. Knee Surg Sports Traumatol Arthrosc 2009, 17:778-781.
25. Olah AV, Llyes I, Szoke A, et al. Urinary homogentisic acid in alkaptonuric and healthy children. Clin Chem Lab Med 2003, 41:356-359.
26. Loken PR, Magera MJ, Introne W, et al. Homogentisic acid interference in routine urine creatinine determination. Mol Genet Metab 2010, 100:103-104.
27. Perrone A, Impara L, Bruni A, Primicerio P, Marini M Radiographic and MRI findings in ochronosis. Radiol Med 2005, 110:349-358.
28. Taylor A, Fraser W, Wilson P, Ranganath L, Gallagher J Ultrastructural analysis of collagen in the arthropathy of alkaptonuria in vivo and in vitro. Osteoarthritis Cartilage 2009, 17(Suppl. 1):S244-S245.
29. Taylor AM, Wlodarski B, Prior IA, et al. Ultrastructural examination of tissue in a patient with alkaptonuric arthropathy reveals a distinct pattern of binding of ochronotic pigment. Rheumatology (Oxford) 2010, 49:1412-1414.
30. Taylor AM, Boyde A, Wilson PJ, et al. The role of calcified cartilage and subchondral bone in the initiation and progression of ochronotic arthropathy in alkaptonuria. Arthritis Rheum 2011, 63:3887-3896.
31. Kruithof E, Baeten D, Veys EM, et al. Case Number 29: Ochronosis: synovial histopathological characteristics. Ann Rheum Dis 2004, 63:130.
32. Taylor A, Prio I, Wlodarski B, et al. Ultrastructural examination of collagen from alkaptonuric tissue provides clues to pathogenesis of ochronosis. Calcif Tissue Int 2008, 83:33.
33. Chow WY, Taylor AM, Reid DG, Gallagher JA, Duer MJ Collagen atomic scale molecular disorder in ochronotic cartilage from an alkaptonuria patient, observed by solid state NMR. J Inherit Metab Dis 2011, 34:1137-1140.
34. Tinti L, Taylor AM, Santucci A, et al. Development of an in vitro model to investigate joint ochronosis in alkaptonuria. Rheumatology (Oxford) 2011, 50:271-277.
35. Taylor A, Fraser W, Wilson P, Ranganath L, Gallagher J Ultrastructural studies on the binding of ochronotic pigment to collagen fibres in cartilage and bone in vivo and in vitro. Calcif Tissue Int 2009, 85:187.
36. Fernandez IS, Cuevas P, Angulo J, et al. Gentisic acid, a compound associated with plant defense and a metabolite of aspirin, heads a new class of in vivo fibroblast growth factor inhibitors. J Biol Chem 2010, 285:11714-11729.
37. Millucci L, Spreafico A, Tinti L, et al. Alkaptonuria is a novel human secondary amyloidogenic disease. Biochim Biophys Acta 2012, 1822:1682-1691.
38. Blivaiss BB, Rosenberg EF, Kutuzov H, Stoner R Experimental ochronosis. Induction in rats by long-term feeding with L-tyrosine. Arch Pathol 1966, 82:45-53.
39. Suwannarat P, Phornphutkul C, Bernardini I, Turner M, Gahl WA Minocycline-induced hyperpigmentation masquerading as alkaptonuria in individuals with joint pain. Arthritis Rheum 2004, 50:3698-3701.
40. Rausing A, Rosen U Black cartilage after therapy with levodopa and methyldopa. Arch Pathol Lab Med 1994, 118:531-535.
41. Hegedus ZL, Nayak U Homogentisic acid and structurally related compounds as intermediates in plasma soluble melanin formation and in tissue toxicities. Arch Int Physiol Biochim Biophys 1994, 102:175-181.
42. Kirkpatrick CJ, Mohr W, Mutschler W Experimental studies on the pathogenesis of ochronotic arthropathy. The effects of homogentisic acid on adult and fetal articular chondrocyte morphology, proliferative capacity and synthesis of proteoglycans in vitro. Virchows Arch B Cell Pathol Incl Mol Pathol 1984, 47:347-360.
43. Moran TJ, Yunis EJ Studies on ochronosis. 2. Effects of injection of homogentisic acid and ochronotic pigment in experimental animals. Am J Pathol 1962, 40:359-369.
44. Fernandez-Canon JM, Granadino B, Beltran-Valero de Bernabe D, et al. The molecular basis of alkaptonuria. Nat Genet 1996, 14:19-24.
45. Laschi M, Tinti L, Braconi D, et al. Homogentisate 1,2 dioxygenase is expressed in human osteoarticular cells: implications in alkaptonuria. J Cell Physiol 2012, 227:3254-3257.
46. Zatkova A An update on molecular genetics of alkaptonuria (AKU). J Inherit Metab Dis 2011, 34:1127-1136.
47. Al-sbou M Novel mutations in the homogentisate 1,2 dioxygenase gene identified in Jordanian patients with alkaptonuria. Rheumatol Int 2012, 32:1741-1746.
48. Vilboux T, Kayser M, Introne W, et al. Mutation spectrum of homogentisic acid oxidase (HGD) in alkaptonuria. Hum Mutat 2009, 30:1611-1619.
49. Montagutelli X, Lalouette A, Coude M, et al. aku, a mutation of the mouse homologous to human alkaptonuria, maps to chromosome 16. Genomics 1994, 19:9-11.
50. Taylor AM, Preston AJ, Paulk NK, et al. Ochronosis in a murine model of alkaptonuria is synonymous to that in the human condition. Osteoarthritis Cartilage 2012, 20:880-886.
51. Introne WJ, Kayser MA, Gahl WA Alkaptonuria. GeneReviews 1993, University of Washington, Seattle, Seattle. R.A. Pagon, T.D. Bird, C.R. Dolan, K. Stephens, M.P. Adam (Eds.).
52. Suwannarat P, O'Brien K, Perry MB, et al. Use of nitisinone in patients with alkaptonuria. Metabolism 2005, 54:719-728.
53. Introne WJ, Perry MB, Troendle J, et al. A 3-year randomized therapeutic trial of nitisinone in alkaptonuria. Mol Genet Metab 2011, 103:307-314.
54. Cox TF, Ranganath L A quantitative assessment of alkaptonuria: testing the reliability of two disease severity scoring systems. J Inherit Metab Dis 2011, 34:1153-1162.
55. Ranganath LR, Cox TF Natural history of alkaptonuria revisited: analyses based on scoring systems. J Inherit Metab Dis 2011, 34:1141-1151.
56. Braconi D, Laschi M, Amato L, et al. Evaluation of anti-oxidant treatments in an in vitro model of alkaptonuric ochronosis. Rheumatology (Oxford) 2010, 49:1975-1983.
57. Tinti L, Spreafico A, Braconi D, et al. Evaluation of antioxidant drugs for the treatment of ochronotic alkaptonuria in an in vitro human cell model. J Cell Physiol 2010, 225:84-91.
58. Zannoni VG, Lomtevas N, Goldfinger S Oxidation of homogentisic acid to ochronotic pigment in connective tissue. Biochim Biophys Acta 1969, 177:94-105.
59. Lustberg TJ, Schulman JD, Seegmiller JE Decreased binding of 14C-homogentisic acid induced by ascorbic acid in connective tissue of rats with experimental alcaptonuria. Nature 1970, 228:770-771.
60. Wolff JA, Barshop B, Nyhan WL, et al. Effects of ascorbic acid in alkaptonuria: alterations in benzoquinone acetic acid and an ontogenic effect in infancy. Pediatr Res 1989, 26:140-144.
61. Englard S, Seifter S The biochemical functions of ascorbic acid. Ann Rev Nutr 1986, 6:365-406.
62. Voshchenko AV Kashin-Beck disease in USSR. Proceedings of the International Workshop on Kashin-Beck Disease and Non-communicable Diseases 1990, World Health Organization, Beijing.
63. Jianbo Y Epidemiological studies on the causes of Kashin-Beck disease. Proceedings of the International Workshop on Kashin-Beck Disease and Non-communicable Diseases 1990, World Health Organization, Beijing.
64. Allander E Kashin-Beck disease. An analysis of research and public health activities based on a bibliography 1849-1992. Scand J Rheumatol Suppl 1994, 99:1-36.
65. Yang CL, Bodo M, Notbohm H, Peng A, Muller PK Fulvic acid disturbs processing of procollagen II in articular cartilage of embryonic chicken and may also cause Kashin-Beck disease. Eur J Biochem 1991, 202:1141-1146.
66. Zou K, Liu G, Wu T, Du L Selenium for preventing Kashin-Beck osteoarthropathy in children: a meta-analysis. Osteoarthritis Cartilage 2009, 17:144-151.
67. Suetens C, Moreno-Reyes R, Chasseur C, et al. Epidemiological support for a multifactorial aetiology of Kashin-Beck disease in Tibet. Int Orthop 2001, 25:180-187.
68. Mathieu F, Begaux F, Suetens C, De Maertelaer V, Hinsenkamp M Anthropometry and clinical features of Kashin-Beck disease in central Tibet. Int Orthop 2001, 25:138-141.
69. Jiang Y, Xu G The relativity between some epidemiological characteristics of Kashin-Beck disease and selenium deficiency. Selenium in biology and medicine 1989, 263-269. Springer, New York. A. Wendel (Ed.).
70. Dongxu M Advances in the pathology of Kashin-Beck disease and its relationship with selenium and other elements. Proceedings of the International Workshop on Kashin-Beck Disease and Non-communicable Diseases 1990, World Health Organization, Beijing.
71. Moreno-Reyes R, Suetens C, Mathieu F, et al. Kashin-Beck osteoarthropathy in rural Tibet in relation to selenium and iodine status. N Engl J Med 1998, 339:1112-1120.
72. Baselt R Selenium. Disposition of toxic drugs and chemicals in man 2002, Biomedical Publications, Foster City, Calif. 6th ed.
73. Ge K, Yang G The epidemiology of selenium deficiency in the etiological study of endemic diseases in China. Am J Clin Nutr 1993, 57(2 Suppl):259S-263S.
74. Xu LQ, Sen WX, Xiong QH, Huang HM, Schramel P Selenium in Kashin-Beck disease areas. Biol Trace Elem Res 1991, 31:1-9.
75. Zhang Y, Guo X, Ping Z, et al. Main source of drinking water and familial aggregation of Kashin-Beck disease: a population based on case-control family study. Ann Epidemiol 2009, 19:560-566.
76. Moreno-Reyes R, Suetens C, Mathieu F, et al. Kashin-Beck disease and iodine deficiency in Tibet. Int Orthop 2001, 25:164-166.
77. Zhang WH, Neve J, Xu JP, Vanderpas J, Wang ZL Selenium, iodine and fungal contamination in Yulin District (People's Republic of China) endemic for Kashin-Beck disease. Int Orthop 2001, 188-190.
78. Tian J, Yan J, Wang W, et al. T-2 toxin enhances catabolic activity of hypertrophic chondrocytes through ROS-NF-kappaB-HIF-2alpha pathway. Toxicol In Vitro 2012, 26:1106-1113.
79. Lu M, Cao J, Liu F, et al. The effects of mycotoxins and selenium deficiency on tissue-engineered cartilage. Cells Tissues Organs 2012, 196:241-250.
80. Chen JH, Xue S, Li S, et al. Oxidant damage in Kashin-Beck disease and a rat Kashin-Beck disease model by employing T-2 toxin treatment under selenium deficient conditions. J Orthop Res 2012, 30:1229-1237.
81. Guan F, Li S, Wang ZL, et al. Histopathology of chondronecrosis development in knee articular cartilage in a rat model of Kashin-Beck disease using T-2 toxin and selenium deficiency conditions. Rheumatol Int 2013, 33:157-166.
82. 2M) and TIMPs. Toxicol In Vitro 2011, 25:492-499.
83. Yan D, Kang P, Li Y, et al. Radiographic findings of Wistar rats fed with T-2 toxin and Kashin-Beck disease-affected diet. Int J Rheum Dis 2011, 14:92-97.
84. Burk RF, Hill KE Selenoprotein P: an extracellular protein with unique physical characteristics and a role in selenium homeostasis. Annu Rev Nutr 2005, 25:215-235.
85. Zagrodzki P, Szmigiel H, Ratajczak R, Szybinski Z, Zachwieja Z The role of selenium in iodine metabolism in children with goiter. Environ Health Perspect 2000, 108:67-71.
86. Utiger RD Kashin-Beck disease-expanding the spectrum of iodine-deficiency disorders [comment]. N Engl J Med 1998, 339:1156-1158.
87. Jordan J, Fang F, Arab L, et al. Low selenium levels are associated with increased odds of radiographic knee and multijoint OA. Osteoarthritis Cartilage 2005, 13(Suppl. A):S35.
88. Sokoloff L Endemic forms of osteoarthritis. Clin Rheum Dis 1985, 11:187-202.
89. Mathieu F, Begaux F, Lan ZY, Suetens C, Hinsenkamp M Clinical manifestations of Kashin-Beck disease in Nyemo Valley, Tibet. Int Orthop 1997, 21:151-156.
90. Wang Y, Yang Z, Gilula LA, Zhu C Kashin-Beck disease: radiographic appearance in the hands and wrists. Radiology 1996, 201:265-270.
91. Hinsenkamp M, Ryppens F, Begaux F, et al. The anatomical distribution of radiological abnormalities in Kashin-Beck disease in Tibet. Int Orthop 2001, 25:142-146.
92. Hinsenkamp M, Mathieu F, Claus W, Collard JF, de Maertelaer V Effects of physical environment on the evolution of Kashin-Beck disease in Tibet. Int Orthop 2009, 33:1085-1088.
93. Reed MH Growth disturbances in the hands following thermal injuries in children. 2. Frostbite. Can Assoc Radiol J 1988, 39:95-99.
94. Yu W, Wang Y, Jiang Y, et al. Kashin-Beck disease in children: radiographic findings in the wrist. Skeletal Radiol 2002, 31:222-225.
95. Fu Q, Cao J, Caterson B, Jordan J, Kraus V The relationship of brachydactyly and joint range of motion in a Kashin-Beck disease region of China. Osteoarthritis Cartilage 2009, 17(Suppl. 1):S187.
96. Xiong G Diagnostic, clinical and radiological characteristics of Kashin-Beck disease in Shaanxi Province, PR China. Int Orthop 2001, 25:147-150.
97. Fang H, Guo X, Farooq U, Xia C, Dong R Development and validation of a quality of life instrument for Kashin-Beck disease: an endemic osteoarthritis in China. Osteoarthritis Cartilage 2012, 20:630-637.
98. Oestreich AE The acrophysis: a unifying concept for understanding enchondral bone growth and its disorders. II. Abnormal growth. Skeletal Radiol 2004, 33:119-128.
99. Dong W, Zhang Y, Liu H, et al. Detection of unsaturated disaccharides, pyridinoline, and hydroxyproline in urine of patients with Kashin-Beck disease: comparison with controls in an endemic area. J Rheumatol 2009, 36:816-821.
100. Li XY, Guo X, Wang LX, et al. [Serum hyaluronic acid, tumor necrosis factor-alpha, vascular endothelial growth factor, NO, and Se levels in adult patients with Kashin-Beck disease]. Nan Fang Yi Ke Da Xue Xue Bao 2007, 27:941-944.
101. Cao J, Li S, Shi Z, et al. Articular cartilage metabolism in patients with Kashin-Beck disease: an endemic osteoarthropathy in China. Osteoarthritis Cartilage 2008, 16:680-688.
102. Tang X, Zhou Z, Shen B, et al. Serum levels of TNF-alpha, IL-1beta, COMP, and CTX-II in patients with Kashin-Beck disease in Sichuan, China. Rheumatol Int 2012, 32:3503-3509.
103. Wang S, Guo X, Tan WH, et al. Detection of serum proteomic changes and discovery of serum biomarkers for Kashin-Beck disease using surface-enhanced laser desorption ionization mass spectrometry (SELDI-TOF MS). J Bone Miner Metab 2008, 26:385-393.
104. Du J, Wu X, Zhang H, et al. Mass spectrometry-based proteomic analysis of Kashin-Beck disease. Mol Med Rep 2010, 3:821-824.
105. Turan B, Balcik C, Akkas N Effect of dietary selenium and vitamin E on the biomechanical properties of rabbit bones. Clin Rheumatol 1997, 16:441-449.
106. Wang SJ, Guo X, Zuo H, et al. Chondrocyte apoptosis and expression of Bcl-2, Bax, Fas, and iNOS in articular cartilage in patients with Kashin-Beck disease. J Rheumatol 2006, 33:615-619.
107. Pasteels JL, Liu FD, Hinsenkamp M, et al. Histology of Kashin-Beck lesions. Int Orthop 2001, 25:151-153.
108. Guo X, Zuo H, Cao CX, et al. Abnormal expression of Col X, PTHrP, TGF-beta, bFGF, and VEGF in cartilage with Kashin-Beck disease. J Bone Miner Metab 2006, 24:319-328.
109. Wang W, Guo X, Chen J, Xu P, Lammi MJ Morphology and phenotype expression of types I, II, III, and X collagen and MMP-13 of chondrocytes cultured from articular cartilage of Kashin-Beck disease. J Rheumatol 2008, 35:696-702.
110. Moreno-Reyes R, Mathieu F, Boelaert M, et al. Selenium and iodine supplementation of rural Tibetan children affected by Kashin-Beck osteoarthropathy. Am J Clin Nutr 2003, 78:137-144.
111. Haubruge E, Chasseur C, Debouck C, et al. The prevalence of mycotoxins in Kashin-Beck disease. Int Orthop 2001, 25:159-161.
112. Sudre P, Mathieu F Kashin-Beck disease: from etiology to prevention or from prevention to etiology?. Int Orthop 2001, 25:175-179.
113. Shi Z, Cao J, Chen J, et al. Butenolide induced cytotoxicity by disturbing the prooxidant-antioxidant balance, and antioxidants partly quench in human chondrocytes. Toxicol In Vitro 2009, 23:99-104.
114. Li SY, Cao JL, Shi ZL, et al. Promotion of the articular cartilage proteoglycan degradation by T-2 toxin and selenium protective effect. J Zhejiang Univ Sci B 2008, 9:22-33.
115. Cheng W, Stabler T, Bolognesi M, Kraus V Selenomethionine inhibits IL-1β induced nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX2) in primary human chondrocytes. Osteoarthritis Cartilage 2009, 17(Suppl. 1):S129.
116. Wai-Ming Cheng A, Bolognesi M, Kraus VB DIO2 modifies inflammatory responses in chondrocytes. Osteoarthritis Cartilage 2012, 20:440-445.
117. Zhai SS, Kimbrough RD, Meng B, et al. Kashin-Beck disease: a cross-sectional study in seven villages in the People's Republic of China. J Toxicol Environ Health 1990, 30:239-259.
118. Chua KH, Aminuddin BS, Fuzina NH, Ruszymah BH Insulin-transferrin-selenium prevent human chondrocyte dedifferentiation and promote the formation of high quality tissue engineered human hyaline cartilage. Eur Cell Mater 2005, 9:58-67.
119. Levander OA Considerations in the design of selenium bioavailability studies. Fed Proc 1983, 42:1721-1725.
120. Xia Y, Hill KE, Byrne DW, Xu J, Burk RF Effectiveness of selenium supplements in a low-selenium area of China. Am J Clin Nutr 2005, 81:829-834.
121. Andriamanalijaona R, Kypriotou M, Bauge C, et al. Comparative effects of 2 antioxidants, selenomethionine and epigallocatechin-gallate, on catabolic and anabolic gene expression of articular chondrocytes. J Rheumatol 2005, 32:1958-1967.
122. Hodgson P, Hughes C, Day M, et al. Development of an in vitro culture system that mimics cartilage pathology in Kashin-Beck disease. Osteoarthritis Cartilage 2005, 13(Suppl. A):S164.
123. Hodgson P, Hughes C, Day C, et al. The effects of selenium and the fungal mycotoxin nivalenol on cartilage matrix metabolism: a culture system to mimic pathology in Kashin-Beck disease. Trans Orthop Res Soc 2006, 31:1413.
124. Yang C, Wolf E, Roser K, Delling G, Muller PK Selenium deficiency and fulvic acid supplementation induces fibrosis of cartilage and disturbs subchondral ossification in knee joints of mice: an animal model study of Kashin-Beck disease. Virchows Arch A Pathol Anat Histopathol 1993, 423:483-491.
125. Peng A, Wang WH, Wang CX, et al. The role of humic substances in drinking water in Kashin-Beck disease in China. Environ Health Perspect 1999, 107:293-296.
126. Ioannidis N, Kurz B, Hansen U, Schunke M Influence of fulvic acid on the collagen secretion of bovine chondrocytes in vitro. Cell Tissue Res 1999, 297:141-147.
127. Debouck C, Haubruge E, Bollaerts P, et al. Skeletal deformities induced by the intraperitoneal administration of deoxynivalenol (vomitoxin) in mice. Int Orthop 2001, 25:194-198.
128. Jianan T, Wenyu Z, Ribang L, et al. Geographic distribution of Kashin-Beck disease in China and the relation of ecological chemico-geography to its occurrence. Proceedings of the International Workshop on Kashin-Beck Disease and Non-communicable Diseases 1990, World Health Organization, Beijing.
129. Jiayun D The geographical distribution characteristics of Kashin-Beck disease in Sichuan province. Proceedings of the International Workshop on Kashin-Beck Disease and Non-communicable Diseases 1990, World Health Organization, Beijing.
130. Shi XW, Guo X, Ren FL, Lu AL, Zhang YZ [Familial aggregation and sibling heritability in Kashin-Beck disease]. Nan Fang Yi Ke Da Xue Xue Bao 2008, 28:1187-1189.
131. Kryukov GV, Castellano S, Novoselov SV, et al. Characterization of mammalian selenoproteomes. Science 2003, 300:1439-1443.
132. Kohrle J, Brigelius-Flohe R, Bock A, et al. Selenium in biology: facts and medical perspectives. Biol Chem 2000, 381:849-864.
133. Shi Y, Lu F, Liu X, et al. Genetic variants in the HLA-DRB1 gene are associated with Kashin-Beck disease in the Tibetan population. Arthritis Rheum 2011, 63:3408-3416.
134. Zhao QM, Guo X, Lai JH, et al. Association of TNF-alpha and Fas gene promoter polymorphism with the risk of Kashin-Beck disease in Northwest Chinese population. Clin Rheumatol 2012, 31:1051-1057.
135. Du XH, Dai XX, Xia Song R, et al. SNP and mRNA expression for glutathione peroxidase 4 in Kashin-Beck disease. Br J Nutr 2012, 107:164-169.
136. Xiong YM, Mo XY, Zou XZ, et al. Association study between polymorphisms in selenoprotein genes and susceptibility to Kashin-Beck disease. Osteoarthritis Cartilage 2010, 18:817-824.
137. Sun W, Wang X, Zou X, et al. Selenoprotein P gene r25191g/a polymorphism and quantification of selenoprotein P mRNA level in patients with Kashin-Beck disease. Br J Nutr 2010, 104:1283-1287.
138. Yang C, Niu C, Bodo M, et al. Fulvic acid supplementation and selenium deficiency disturb the structural integrity of mouse skeletal tissue. An animal model to study the molecular defects of Kashin-Beck disease. Biochem J 1993, 289(Pt 3):829-835.
139. Moreno-Reyes R, Egrise D, Neve J, Pasteels JL, Schoutens A Selenium deficiency-induced growth retardation is associated with an impaired bone metabolism and osteopenia. J Bone Miner Res 2001, 16:1556-1563.
140. Sasaki S, Iwata H, Ishiguro N, Habuchi O, Miura T Low-selenium diet, bone, and articular cartilage in rats. Nutrition 1994, 10:538-543.
141. Ren FL, Guo X, Zhang RJ, et al. Effects of selenium and iodine deficiency on bone, cartilage growth plate and chondrocyte differentiation in two generations of rats. Osteoarthritis Cartilage 2007, 15:1171-1177.
142. Guanghou N, Baozhen Z, Yupie Z, et al. Studies on the bacteria toxin etiology of Kashin-Beck disease. Proceedings of the International Workshop on Kashin-Beck Disease and Non-communicable Diseases; 1990 1990, World Health Organization, Beijing.
143. Kurz B, Jost B, Schunke M Dietary vitamins and selenium diminish the development of mechanically induced osteoarthritis and increase the expression of antioxidative enzymes in the knee joint of STR/1N mice. Osteoarthritis Cartilage 2002, 10:119-126.
144. Downey CM, Horton CR, Carlson BA, et al. Osteo-chondroprogenitor-specific deletion of the selenocysteine tRNA gene, Trsp, leads to chondronecrosis and abnormal skeletal development: a putative model for Kashin-Beck disease. PLoS Genet 2009, 5:e1000616.
145. Jirong Y, Huiyun P, Zhongzhe Y, et al. Sodium selenite for treatment of Kashin-Beck disease in children: a systematic review of randomised controlled trials. Osteoarthritis Cartilage 2012, 20:605-613.
146. Yang GQ, Xia YM Studies on human dietary requirements and safe range of dietary intakes of selenium in China and their application in the prevention of related endemic diseases. Biomed Environ Sci 1995, 8:187-201.
147. US Environmental Protection Agency Selenium and compounds (CASRN 7782-49-2). Integrated Risk Information System [updated January 3, 2006; cited January 16, 2006]. Available at, Accessed [January 16, 2006]. http://www.epa.gov/iris/subst/0472.htm.
148. Mathieu F, Suetens C, Begaux F, De Maertelaer V, Hinsenkamp M Effects of physical therapy on patients with Kashin-Beck disease in Tibet. Int Orthop 2001, 25:191-193.
149. Liu W, Liu G, Pei F, et al. Kashin-Beck disease in Sichuan, China: report of a pilot open therapeutic trial. J Clin Rheumatol 2012, 18:8-14.
150. Tang X, Pei FX, Zhou ZK, et al. A randomized, single-blind comparison of the efficacy and tolerability of hyaluronate acid and meloxicam in adult patients with Kashin-Beck disease of the knee. Clin Rheumatol 2012, 31:1079-1086.
151. Luo R, Liu G, Liu W, et al. Efficacy of celecoxib, meloxicam and paracetamol in elderly Kashin-Beck disease (KBD) patients. Int Orthop 2011, 35:1409-1414.
152. Liu FD, Wang ZL, Hinsenkamp M Osteotomy at the knee for advanced cases of Kashin-Beck disease. Int Orthop 1998, 22:87-91.
153. Stone R A medical mystery in middle China. Science 2009, 324:1378-1381.
154. Ministry of Public Health Diagnostic criteria of Kaschin Beck disease 1995, Beijing, China.